Expertise in
20
conditions

Marc Fila

CHU Robert Debré
Paris, FR 
Expertise in
20
conditions
CHU Robert Debré
Paris, FR 
OverviewLocationsClinical Research

Overview

Marc Fila practices in Paris, France. Mr. Fila is highly rated in 20 conditions, according to our data. His top areas of expertise are D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Nephrocalcinosis, and Kidney Transplant.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CHU Robert Debré
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Enrollment Status: Terminated
Publish Date: September 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

85 Total Publications

Corrigendum to "Genotype-Phenotype Correlations in Denys-Drash Syndrome in Children" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1205-1212].
Corrigendum to "Genotype-Phenotype Correlations in Denys-Drash Syndrome in Children" [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1205-1212].
Journal: Kidney international reports
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fila's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile